|
As
of March 31, 2023, there were the following potentially dilutive securities that were excluded from diluted net loss per share because
their effect would be anti-dilutive (all shares adjusted to reflect a 40:1 reverse stock split effected on March 9, 2022):
SCHEDULE
OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE
| Shares from common stock options |
|
|
177,815 |
|
| Shares from common stock warrants |
|
|
50,000 |
|
| Shares from the conversion of convertible notes and accrued interest |
|
|
- |
|
| Shares from the conversion of Series A Stock inclusive of cumulative dividends |
|
|
242,800 |
|
| Shares from the conversion of Series B Preferred Stock inclusive of dividends |
|
|
301,435 |
|
| Total |
|
|
727,094 |
|
As
of March 31, 2022, there were the following potentially dilutive securities that were excluded from diluted net loss per share because
their effect would be anti-dilutive (all shares adjusted to reflect a 40:1 reverse stock split effected on March 9, 2022):
| Shares from common stock options |
|
|
177,815 |
|
| Shares from common stock warrants |
|
|
37,083 |
|
| Shares from the conversion of convertible notes and accrued interest |
|
|
77,117 |
|
| Shares from the conversion of Series A Stock inclusive of cumulative dividends |
|
|
108,480 |
|
| Shares from the conversion of Series B Preferred Stock inclusive of dividends |
|
|
265,555 |
|
| Total |
|
|
666,050 |
|
|